RBC analysts say Athenex could achieve 'blockbuster sales in breast and gastric cancer'

The lofty view from a respected industry analyst, who give Athenex shares a $35 price target.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 17, 2017 Category: Pharmaceuticals Authors: Dan Miner Source Type: news